Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.40 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530386 | 1.00 | NQO1 (0.44) | NQO1GABRA5HPGDSSOS2RECQL | |
| SCHEMBL30460302 | 0.79 | PDE2A (0.48) | BTK | |
| SCHEMBL3081309 | 0.79 | BTK (0.38) | BTK | |
| SCHEMBL6161278 | 0.79 | PDE2A (0.48) | BTK | |
| SCHEMBL3086121 | 0.79 | BTK (0.41) | BTK | |
| SCHEMBL34469261 | 0.79 | GABRA5 (0.40) | NQO1GABRA5SOS2CTSKMGLL | |
| SCHEMBL2952806 | 0.79 | GABRA5 (0.49) | NQO1GABRA5BTKP2RX3MGLL | |
| SCHEMBL14635657 | 0.79 | GABRA5 (0.40) | NQO1GABRA5SOS2CTSKMGLL | |
| SCHEMBL26750064 | 0.78 | NUDT1 (0.46) | GABRA5CTSK | |
| SCHEMBL23704126 | 0.78 | GRM5 (0.39) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111302968-B | Synthesis method of amide nitrogen trifluoromethyl compound | 中国科学院上海有机化学研究所 | 2021-06-08 | — | — | CN | claimed |
| CN-111302968-A | Synthesis method of amide nitrogen trifluoromethyl compound | 中国科学院上海有机化学研究所 | 2020-06-19 | — | — | CN | claimed |
| CN-108699006-A | 3- ((hetero-) aryl) -8-amino-2-oxo-1, 3-aza-spiro- [4.5] -decane derivative | 格吕伦塔尔有限公司 | 2018-10-23 | — | — | CN | claimed |
| US-4824953-A | Multi-step process for producing 5-hydroxy-N-(6-oxo-piperidyl-methyl)-2-(2,2,2-trifluoro-ethoxy)-benzamide and derivatives | RIKER LABORATORIES, INC. (US) | 1989-04-25 | — | — | US | claimed |
| US-20240246980-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024092222-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-06-24 | — | — | US | disclosed |
| CN-111302968-B | Synthesis method of amide nitrogen trifluoromethyl compound | 中国科学院上海有机化学研究所 | 2021-06-08 | — | — | CN | disclosed |
| WO-2021094209-A1 | SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2020223136-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-0630264-A4 | LIGANDS FOR IMPROVING METAL CHELATE FORMATION KINETICS. | MALLINCKRODT MEDICAL INC (US) | 1994-10-17 | — | — | EP | disclosed |
| US-5280027-A | Quinazoline containing compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| WO-1993015771-A1 | LIGANDS FOR IMPROVING METAL CHELATE FORMATION KINETICS | MALLINCKRODT MEDICAL, INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| EP-0459730-A2 | Anti-tumour compounds | ZENECA LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-4824953-A | Multi-step process for producing 5-hydroxy-N-(6-oxo-piperidyl-methyl)-2-(2,2,2-trifluoro-ethoxy)-benzamide and derivatives | RIKER LABORATORIES, INC. (US) | 1989-04-25 | — | — | US | disclosed |
| US-4656285-A | Compound 2-acetamidomethyl-6-methoxy-pyridine | RIKER LABORATORIES, INC. (US) | 1987-04-07 | — | — | US | disclosed |
| US-4555573-A | Certain 6-benzamidomethyl-2(1H)-pyridone derivatives | RIKER LABORATORIES, INC. (US) | 1985-11-26 | — | — | US | disclosed |
| US-4496734-A | Metabolite | RIKER LABORATORIES, INC. (US) | 1985-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246980-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX2, MRGPRX4 | NQO1 4424/4885GABRA5 316/4885HPGDS 274/4885 |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | APLNR, AGTR1, AGTR2 | NQO1 3981/4885GABRA5 273/4885HPGDS 424/4885 |
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | NQO1 643/4885GABRA5 75/4885HPGDS 942/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | NQO1 3981/4885GABRA5 273/4885HPGDS 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.